Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 7/2008

01-05-2008 | Adis Drug Profile

Mosapride

In Gastrointestinal Disorders

Authors: Monique P. Curran, Dean M. Robinson

Published in: Drugs | Issue 7/2008

Login to get access

Abstract

  • ▴ Mosapride was effective in improving overall symptoms in patients with gastrointestinal disorders, including chronic gastritis, gastro-oesophageal reflux disease and functional dyspepsia.
  • ▴ Mosapride was more effective than teprenone in improving gastric stasis symptoms and gastric pain after 2 weeks of therapy (p < 0.001) in an open-label trial in 1042 patients with functional dyspepsia.
  • ▴ Mosapride was as effective as famotidine and itopride, but more effective than tandospirone, in improving overall or individual symptoms of functional dyspepsia in randomized trials. However, in one randomized, double-blind trial in patients with mild to severe disease, the improvement in overall symptoms of functional dyspepsia did not differ significantly between mosapride or placebo treatment.
  • ▴ Mosapride was well tolerated, with diarrhoea/loose stools, dry mouth, malaise and headache being reported in <5% of patients.
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
Mizuta Y, Shikuwa S, Isomoto H, et al. Recent insights into digestive motility in functional dyspepsia. J Gastroenterol 2006 Nov;41(11): 1025–40PubMedCrossRef
2.
Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999 Sep; 45 Suppl. 2: II43–7PubMedCrossRef
3.
Grundy D, AL-Chaer ED, Aziz Q, et al. Fundamentals of neurogastroenterology: basic science. Gastroenterology 2006; 130(5): 1391–411PubMedCrossRef
4.
Makimoto N, Sukurai-Yamashita Y, Furuichi A, et al. In vivo assessment of acceleration of motor activity associated with acetylcholine release via 5-hydroxytriptamine. Jpn J Pharmacol 2002; 90: 28–35PubMedCrossRef
5.
Carlsson L, Amos GJ, Andersson B, et al. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther 1997 Jul; 282(1): 220–7PubMed
6.
Toga T, Kohmura Y, Kawatsu R. The 5-HT4 agonists cisapride, mosapride, and CJ-033466, a novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. J Pharmacol Sci 2007 Oct; 105(2): 207–10PubMedCrossRef
7.
Potet F, Bouyssou T, Escande D. Gastrointestinal prokinetic drugs have a different affinity for the human cardiac human ether-à-gogo K+ channel. J Pharmacol Exp Ther 2001; 289(3): 1007–12
8.
Yoshida N, Kato S, Ito T. Mosapride citrate: gastroprokinetic. Drugs Future 1993; 18(6): 513–5
9.
Karasawa T, Yoshida N, Furukawa K, et al. Comparison of gastrokinetic effects of AS-4370, cisapride and BRL 24924. Eur J Pharmacol 1990 Jul 6; 183: 2181CrossRef
10.
Yoshida N, Omoya H, Furukawa K, et al. Pharmacological studies on mosapride citrate (AS-4370), a gastroprokinetic agent (1): comparison with cisapride and metoclopramide [in Japanese]. Jpn Pharmacol Ther 1993; 21(9): 249–64
11.
Yoshida N, Omoya H, Oka M, et al. AS-4370, a novel gastrokinetic agent free of dopamine D2 receptor antagonist properties. Arch Int Pharmacodyn Ther 1989; 300: 51–67PubMed
12.
Yoshida N, Omoya H, Kato S, et al. Pharmaocological effects of the new gastroprokinetic agent mosapride citrate and its metabolite in experimental animals. Arzneimittelforschung 1993; 43(10): 1078–83PubMed
13.
Hamelin B, Bredberg E, Röhss K, et al. Effects of mosapride on oesophageal motility in humans [abstract no. A51]. Dig Dis Sci 1996 Sep; 41(9): 1892
14.
Mitsufuji S, Nakao H, Taniguchi J, et al. Effect of mosapride citrate on esophageal motility in healthy subjects and patients with gastroesophageal reflux disease [in Japanese]. Prog Med 2002; 22(3): 801–5
15.
Ruth M, Finizia C, Cange L, et al. The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2003 Oct; 15(10): 1115–21PubMedCrossRef
16.
Cho YK, Choi M-G, Han HW, et al. The effect of mosapride on esophageal motility and bolus transit in asymptomatic volunteers. J Clin Gastroenterol 2006 Apr; 40(4): 286–92PubMedCrossRef
17.
Kanaizumi T, Nakano H, Matsui Y, et al. Prokinetic effect of AS-4370 on gastric emptying in healthy adults. Eur J Clin Pharmacol 1991; 41(4): 335–7PubMedCrossRef
18.
Suyama T, Tokubayashi F, Omatsu Y, et al. Accelerating effect of AS-4370 (mosapride) on gastric emptying time (double sampling test method) and its clinical efficacy on chronic gastritis accompanied by epigastric symptoms [in Japanese]. Jpn Arch Intern Med 1993; 40(7): 175–83
19.
Wei W, Ge Z-Z, Lu H, et al. Effect of mosapride on gastrointestinal transit time and diagnostic yield of capsule endoscopy. J Gastroenterol Hepatol 2007 Oct; 22(10): 1605–8PubMedCrossRef
20.
Asai H, Udaka F, Hirano M, et al. Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson’s disease. Parkinsonism Relat Disord 2005; 11(8): 499–502PubMedCrossRef
21.
Asakawa H, Hayashi I, Fukui T, et al. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy. Diabetes Res Clin Pract 2003; 61(3): 175–82PubMedCrossRef
22.
Yamada M, Hongo M. Effects of prokinetic agents: comparison between AS4370 and EM523L. Gastroenterol Jpn 1993 Dec; 28(6): 836
23.
Inui A, Yoshikawa T, Nagai R, et al. Effects of mosapride citrate, a 5-HT4 receptor agonist, on colonie motilit in conscious guinea pigs. Jpn J Pharmacol 2002; 90: 313–20PubMedCrossRef
24.
Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 anatgonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005; 20(6): 680–6PubMedCrossRef
25.
Kojima Y, Fujii H, Katsui R, et al. Enhancement of the intrinsic defecation reflex by mosapride, a 5-HT4 agonist, in chronically lumbosacral denervated guinea pigs. J Smooth Muscle Res 2006; 42(5): 139–47PubMedCrossRef
26.
Kojima Y, Nakagawa T, Katsui R, et al. A 5-HT4 agonist, mosapride, enhances intrinsic rectorectal and rectonal reflexes after removal of extrinsic nerves in guinea pigs. Am J Physiol Gastrointest Liver Physiol 2005; 289: G351–60PubMedCrossRef
27.
Ruth M, Hamelin B, Röhss K, et al. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998 Jan; 12(1): 35–40PubMedCrossRef
28.
Itoh H, Nagano T, Takeyama M. Effects of mosapride citrate on human plasma levels of motilin, gastrin, somatostatin, and secretin. Biol Pharm Bull 2001 Sep; 24(9): 1072–5PubMedCrossRef
29.
Hayakawa A, Kawahara K, Ueda Y, et al. Clinical study of AS-4370 in non-ulcer dyspepsia: effects of AS-4370 on upper abdominal symptoms and on hormones [in Japanese]. Rinsho Iyaku 1992; 8(3): 639–45
30.
Kii Y, Ito T. Effects of 5-HT4-receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles. J Cardiovasc Pharmacol 1997 May; 29(5): 670–5PubMedCrossRef
31.
Katoh T, Saitoh H, Ohno N, et al. Drug interaction between mosapride and erythromycin without electrocardiographic changes. Jpn Heart J 2003 Mar; 44(2): 225–34PubMedCrossRef
32.
Horii S, Takeda T, Fujimoto Y, et al. Clinical study on safety of mosapride in combination therapy with psychiatric drugs [in Japanese]. Rinsho Iyaku 2000; 16(2): 153–62
33.
Takeuchi Y, Watanabe H, Imawari M. Mosapride citrate, a serotonin HT4 selective agonist, beneficially affects pharmacokinetics of proton pump inhibitor [abstract no. T1693]. Gastroenterology 2005 Apr; 128 (4 Suppl. 2): A–531
34.
Sakashita M, Yamaguchi T, Miyazaki H, et al. Pharmaco-kinetics of the gastrokinetic agent mosapride citrate after single and multiple oral administrations in healthy subjects. Arzneimittelforschung 1993; 43(8): 867–72PubMed
35.
Ogihara T, Higaki J, Azuma J, et al. Pharmacokinetic study of AS-4370 in the elderly: comparison with the young [in Japanese]. Rinsho Iyaku 1994; 10(11): 2489–97
36.
Dainippon Pharmaceutical Co., Ltd. Gasmotin®: mosapride citrate preparation. Prescribing information. Osaka, 2004
37.
Miyoshi A, Yoshida Y, Masamune O, et al. Phase II study of two dosage regimens of AS-4370 tablet: randomised comparison of doses taken before and after meals [in Japanese]. Rinsho Iyaku 1998; 14(6): 1025–36
38.
Misawa T, Okabe H, Chijiiwa Y, et al. Clinical study of AS-4370 on upper abdominal symptoms in chronic gastritis [in Japanese]. Rinsho Iyaku 1993; 9(9): 2167–76
39.
Toyota T, Hongo M, Sato M, et al. Clinical evaluation of mosapride citrate (AS-4370) on dyspepsia symptoms in chronic gastritis [in Japanese]. Rinsho Iyaku 1993; 9(8): 1887–95
40.
Miyoshi A, Miwa T, Harasawa S, et al. Dose-finding study of AS-4370 (mosapride citrate) in patients with chronic gastritis [in Japanese]. Rinsho Iyaku 1998; 14(6): 1069–90
41.
Miyoshi A, Miwa T, Harasawa S, et al. Clinical evaluation of AS-4370 on epigastric symptoms associated with chronic gastritis [in Japanese]. Rinsho Iyaku 1998; 14(6): 1037–53
42.
Miyoshi A, Miwa T, Harasawa S, et al. Dose finding study of AS-4370 in patients with non-ulcer dyspepsia [in Japanese]. Rinsho Iyaku 1990 Nov; 6: 2295–310
43.
Miyoshi A, Sekiguchi T, Miwa T, et al. Clinical assessment of AS-4370 in the treatment of reflux oesophagitis: dose-comparison study by randomization [in Japanese]. Rinsho Iyaku 1993; 9(6): 1327–41
44.
Hongo M. Initial approach and pharmacotherapy for functional dyspepsia: a large clinical trial in Japan [abstract no. T1247, plus poster]. Gastroenterology 2006 Apr; 130 (4 Suppl. 2): 506
45.
Hallerbäck BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002 May; 16(5): 959–67PubMedCrossRef
46.
Kinoshita Y, Hashimoto T, Kawamura A, et al. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment Pharmacol Ther 2005 Jun; 21 Suppl. 2: 37–41CrossRef
47.
Otaka M, Jin M, Odashima M, et al. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther 2005 Jun; 21 Suppl. 2: 42–6CrossRef
48.
Seno H, Nakase H, Chiba T. Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. Aliment Pharmacol Ther 2005 Jan 1; 21 Suppl. 2: 32–6CrossRef
49.
Amarapurkar DN, Rane P. Randomised, double-blind, comparative study to evaluate the efficacy and safety of ganaton (itopride hydrochloride) and mosapride citrate in the management of functional dyspepsia. J Indian Med Assoc 2004 Dec; 102(12): 735–7, 760PubMed
50.
Miyoshi A, Sekiguchi T, Harasawa S, et al. Clinical evaluation of mosapride (AS-4370) on gastroesophageal reflux disease: multi-centered double-blind comparative study with cisapride [in Japanese]. Rinsho Iyaku 1998; 14(6): 1055–68
51.
Madan K, Ahuja V, Kashyap PC, et al. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus 2004; 17(4): 274–8PubMedCrossRef
52.
Kanaizumi T, Nakano H, Kuriya N. Clinical evaluation of AS-4370 in ambulatory patients with epigastric digestive tract disorder after gastric surgery by double-blind study [in Japanese]. Rinsho Iyaku 1992; 8(7): 1559–68
53.
Kanaizumi T, Nakano H. Clinical evaluation of long-term administration of mosapride citrate (AS-4370) in postoperative ambulatory patients with epigastric digestive tract disorders [in Japanese]. Rinsho Iyaku 1993; 9(8): 1879–86
54.
Kanaizumi T, Nakano H, Kuriya N. Clinical evaluation of AS-4370 in hospitalized patients with epigastric symptoms after gastric surgery in a double-blind comparative study [in Japanese]. Rinsho Iyaku 1992; 8(12): 2831–40
55.
Odaka T, Suzuki T, Seza A, et al. Serotonin 5-HT4 receptor agonist (mosapride citrate) [in Japanese]. Nippon Rinsho 2006; 64(8): 1491–4PubMed
56.
Hiyama T, Yoshihara M, Matsuo K, et al. Treatment of functional dyspepsia with serotonin agonists: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2007 Oct; 22(10): 1566–70PubMedCrossRef
57.
Oikawa T, Takemoto Y, Haramu K. Postmarketing surveillance of mosapride citrate (Gasmotin®) in patients with non-ulcer dyspepsia on long-term administration [in Japanese]. Rinsho Iyaku 2005; 21(8): 831–7
58.
Ohki R, Takahashi M, Mizuno O, et al. Torsades de pointes ventricular tachycardia induced by mosapride and flecainide in the presence of hypokalemia. Pacing Clin Electrophysiol 2001 Jan; 24(1): 119–21PubMedCrossRef
59.
60.
61.
Dainippon Sumitomo Pharma Co. Ltd., Eisai Co.. Dainippon Sumitomo Pharma and Eisai signed licensing agreement for Gasmotin®, a gastroprokinetic agent, for countries in Asia including ASEAN members [online]. Available from URL: http://​www.​ds-pharma.​co.​jp [Accessed 2008 Jan 17]
Metadata
Title
Mosapride
In Gastrointestinal Disorders
Authors
Monique P. Curran
Dean M. Robinson
Publication date
01-05-2008
Publisher
Springer International Publishing
Published in
Drugs / Issue 7/2008
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200868070-00007

Other articles of this Issue 7/2008

Drugs 7/2008 Go to the issue

Review Article

Renal Disease in Patients with HIV Infection

Adis Drug Evaluation

Posaconazole

Correspondence

Drugs in the Newspapers

Leading Article

Novel Thrombopoietic Agents

Therapy in Practice

Management of Breakthrough Pain in Patients with Cancer

Review Article

Guide to the Use of Proton Pump Inhibitors in Adult Patients